TNF and Crohn disease: In 1998, the drug infliximab, developed from a murine-human chimeric anti-tumor necrosis factor (TNF) monoclonal antibody that binds diverse TNF moieties, was approved by the US Food and Drug Administration for the treatment of Crohn's disease [1].